Abiopharma

News list

(10% Negative) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 5:09 p.m.
🌍 Sanofi (SNY) - Form 6-K Filing

Filing Date: 2022-05-25

Accepted: 2022-05-25 13:53:39

Event Type: Clinical Trial Update

Event Details:

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis. Eosinophile esophagealitis is a chronic, progressive inflammatory disease driven by type 2 inflammation that damages the esophagus.
💼 Business Developments:
- ✅ Partnership/Collaboration
- ❌ Acquisition Activity: Not reported
- ❌ Licensing Agreement: Not reported
- ✅ Regulatory Milestone
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Email: sally.bain@sanofi.com